Health & Environmental Research Online (HERO)


Print Feedback Export to File
7173193 
Journal Article 
A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors 
Ning, N; Zhang, J; Deng, X; Chen, Q; Ren, R; Yu, Y; Wu, Min; Zhang, R; Zhang, T; Zhu, C; Huang, Lei; Yun, CaiH; Benes, CH; , 
2018 
Yes 
Cancer Research
ISSN: 0008-5472
EISSN: 1538-7445 
AMER ASSOC CANCER RESEARCH 
PHILADELPHIA 
5949-5957 
30135190 
WOS:000447552500020 
Microtubule inhibitors as chemotherapeutic drugs are widely used for cancer treatment. However, the development of multidrug resistance (MDR) in cancer is a major challenge for microtubule inhibitors in their clinical implementation. From a high-throughput drug screen using cells transformed by oncogenic RAS, we identify a lead heteroaryl amide compound that blocks cell proliferation. Analysis of the structure-activity relationship indicated that this series of scaffolds (exemplified by MP-HJ-1b) represents a potent inhibitor of tumor cell growth. MP-HJ-1b showed activities against a panel of more than 1,000 human cancer cell lines with a wide variety of tissue origins. This compound depolymerized microtubules and affected spindle formation. It also induced the spike-like conformation of microtubules in vitro and in vivo, which is different from typical microtubule modulators. Structural analysis revealed that this series of compounds bound the colchicine pocket at the intradimer interface, although mostly not overlapping with colchicine binding. MP-HJ-1b displayed favorable pharmacological properties for overcoming tumor MDR, both in vitro and in vivo. Taken together, our data reveal a novel scaffold represented by MP-HJ-1b that can be developed as a cancer therapeutic against tumors with MDR.Significance: Paclitaxel is a widely used chemotherapeutic drug in patients with multiple types of cancer. However, resistance to paclitaxel is a challenge. This study describes a novel class of microtubule inhibitors with the ability to circumvent multidrug resistance across multiple tumor cell lines. (C) 2018 AACR.